Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma


- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors -

See the article here:
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Related Posts